Think about this—what if one of the most powerful tools we need to fight superbugs was discovered over 100 years ago, floating silently in water, invisible to the eye?
Then Imagine this: you're battling a life-threatening infection that no antibiotic can touch.
Doctors have tried everything, yet the bacteria causing your illness continue to multiply.
Now picture tiny viruses, nature's own bacteria hunters -coming to your rescue, selectively targeting and destroying those harmful bacteria while leaving your healthy cells untouched.
This isn't science fiction.
These microscopic heroes are called bacteriophages (or simply "phages"), and they've been quietly working in nature for thousands of years before we even knew they existed.
The story of bacteriophages begins over a century ago with two remarkable scientists whose work was separated by oceans but connected by discovery.
Way back in 1896, British bacteriologist Ernest Hankin noticed something strange while studying cholera outbreaks in India.
Water from the Ganges River seemed to contain an unknown substance that could kill cholera bacteria.
He described this mysterious antibacterial agent in his reports, but lacked the tools to identify what it was.
Two decades later, French-Canadian microbiologist Félix d'Herelle made a breakthrough while investigating dysentery outbreaks.
He discovered what he called "an invisible microbe" that could destroy bacteria.
d'Herelle was the first to isolate these viruses, study them methodically, and gave them their name—bacteriophage, meaning "bacteria eater."
He even pioneered their use as treatment for bacterial infections, establishing the foundations of phage therapy.
A Story That’s Still Unfolding - From Spotlight to Shadows and Back Again
Since then, our understanding of bacteriophages, or phages for short, has come a long way.
After d'Herelle's discoveries, phage therapy showed early promise and was used in various parts of the world.
However, with the discovery of antibiotics in the 1940s, Western medicine largely abandoned phage research.
Antibiotics were easier to mass-produce, store, and administer—they became the miracle drugs of their era.
For decades, they stayed in the shadows, especially with the rise of antibiotics.
Fast forward to today, and we're witnessing a renaissance in phage research, driven by several factors:
First
the alarming rise of antibiotic-resistant "superbugs" has forced us to seek alternatives. When common infections no longer respond to available antibiotics, phages offer a potential solution.
Second
advances in technology—particularly metagenomics—have revolutionized how we study phages.
Metagenomics allows scientists to analyze genetic material recovered directly from environmental samples.
This approach has revealed phages are the most abundant biological entities on Earth, with estimates suggesting there are 10^31 (that's 10 with 31 zeros!) phage particles globally.
Through metagenomics, we've discovered incredible phage diversity and understood more about their complex relationships with bacteria.
We now know phages play crucial roles in bacterial evolution, gene transfer, and maintaining ecological balance in every environment from oceans to soil to the human gut.
The resurgence of interest in phages isn't just theoretical—it's saving lives.
In Europe, particularly in Poland and Georgia, phage therapy centers have been treating patients with multi-drug resistant infections for decades.
Their experience shows phages can be effective when antibiotics fail.
In the United States, several remarkable cases have captured medical attention.
Perhaps most famous is the case of Tom Patterson, a professor who contracted a deadly antibiotic-resistant Acinetobacter baumannii infection while traveling in Egypt.
After months in a coma with no effective treatments left, physicians obtained emergency approval to use experimental phage therapy.
Within days of receiving the phages, Patterson began recovering.
Similar successful "compassionate use" cases have been documented around the world, offering hope to patients with few or no other options.
What’s so remarkable about phages is that they don’t just attack bacteria—they can be incredibly precise.
This means they can target the bad guys without wiping out the good bacteria our bodies need.
This October, something exciting is happening.
From October 12–14, 2025, nearly 500 researchers and clinicians from across the globe will gather in Washington, DC for the very First Conference on Bacteriophages: Biology, Dynamics, and Therapeutics.
They’ll be talking about breakthroughs, new clinical applications, and what’s next for phage therapy in real-world settings.
For those of us in infectious diseases, microbiology, and patient care—it’s not just another conference. It’s a chance to witness history in the making.
This conference represents a pivotal moment as scientists, clinicians, and policymakers come together to advance our understanding and implementation of phage therapy
A Gentle Call to Action
If you’re a physician, researcher, or clinician who cares about the future of infectious diseases—this matters.
Because phages aren’t just a quirky part of microbiology’s past. They’re becoming a vital part of our future.
Let’s stay curious. Let’s keep asking bold questions.
And most importantly, let’s continue to spread knowledge wrapped in kindness — because healing is about more than just killing bacteria.
It’s about offering real hope, grounded in science, and delivered with compassion.
Will I see you in Washington?